Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CEMINASDAQ:MBRXNYSE:NHWKNASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEMIChembio Diagnostics$0.46$0.43$0.19▼$1.24$16.71M1.85661,416 shs351,642 shsMBRXMoleculin Biotech$0.32+7.5%$0.80$0.25▼$4.71$4.27M1.391.91 million shs2.36 million shsNHWKNightHawk Biosciences$0.39$0.26▼$1.16$10.78M0.1997,242 shs173,100 shsTNXPTonix Pharmaceuticals$37.30+3.7%$29.45$6.76▼$130.00$264.71M2.06953,290 shs1.15 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEMIChembio Diagnostics0.00%0.00%0.00%0.00%0.00%MBRXMoleculin Biotech+7.49%+6.92%-63.81%-66.23%-91.13%NHWKNightHawk Biosciences0.00%0.00%0.00%0.00%0.00%TNXPTonix Pharmaceuticals+3.67%+4.57%-6.28%+114.49%-49.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCEMIChembio DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/AMBRXMoleculin Biotech3.0664 of 5 stars3.52.00.00.03.31.71.3NHWKNightHawk BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ATNXPTonix Pharmaceuticals2.7746 of 5 stars3.52.00.00.01.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCEMIChembio Diagnostics 0.00N/AN/AN/AMBRXMoleculin Biotech 3.00Buy$4.001,132.67% UpsideNHWKNightHawk Biosciences 0.00N/AN/AN/ATNXPTonix Pharmaceuticals 3.00Buy$585.001,468.36% UpsideCurrent Analyst Ratings BreakdownLatest CEMI, MBRX, TNXP, and NHWK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.006/3/2025TNXPTonix PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCEMIChembio Diagnostics$48.34M0.35N/AN/A$0.48 per share0.95MBRXMoleculin BiotechN/AN/AN/AN/A$1.77 per shareN/ANHWKNightHawk Biosciences$6.38M0.00N/AN/A$2.82 per share0.00TNXPTonix Pharmaceuticals$10.09M27.21N/AN/A$31.82 per share1.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCEMIChembio Diagnostics-$23.29M-$1.20N/A∞N/A-47.03%-113.57%-38.22%N/AMBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)NHWKNightHawk Biosciences-$43.44M-$1.99N/AN/AN/A-2,333.27%-91.62%-56.48%N/ATNXPTonix Pharmaceuticals-$130.04M-$1,963.61N/AN/AN/A-1,313.87%-120.96%-101.28%8/15/2025 (Estimated)Latest CEMI, MBRX, TNXP, and NHWK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/A5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCEMIChembio DiagnosticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ANHWKNightHawk BiosciencesN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCEMIChembio DiagnosticsN/A1.231.04MBRXMoleculin BiotechN/A1.351.35NHWKNightHawk Biosciences0.270.990.99TNXPTonix PharmaceuticalsN/A12.3111.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCEMIChembio Diagnostics8.65%MBRXMoleculin Biotech15.52%NHWKNightHawk Biosciences21.16%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipCEMIChembio Diagnostics3.30%MBRXMoleculin Biotech1.90%NHWKNightHawk Biosciences15.90%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCEMIChembio Diagnostics33736.73 million35.51 millionNot OptionableMBRXMoleculin Biotech2014.13 million13.86 millionNot OptionableNHWKNightHawk Biosciences7726.08 million21.94 millionOptionableTNXPTonix Pharmaceuticals507.36 million7.36 millionNot OptionableCEMI, MBRX, TNXP, and NHWK HeadlinesRecent News About These CompaniesTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7% - Here's WhyJuly 1 at 3:40 PM | marketbeat.comTonix Pharmaceuticals announces inclusion in Russell 3000, Russell 2000 indexesJune 30 at 7:03 PM | msn.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 2.4% - Should You Buy?June 30 at 1:56 PM | marketbeat.comTonix Pharmaceuticals to be added to Russell 3000, Russell 2000 indexesJune 30 at 8:14 AM | seekingalpha.comTonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJune 30 at 7:00 AM | globenewswire.comTonix Pharmaceuticals Holding Corp. - TNXP | Barron'sJune 29 at 11:44 PM | barrons.comTNXP | Tonix Pharmaceuticals Holding Corp. Stock Overview (U.S.: Nasdaq) - Barron'sJune 27, 2025 | barrons.comTonix Pharmaceuticals Holding Corp News (TNXP) - Investing.comJune 27, 2025 | investing.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 2.4% - Here's WhyJune 27, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 1.7% - Still a Buy?June 26, 2025 | marketbeat.comTonix Pharmaceuticals Holding Corp TNXP Company Vitals - U.S. NewsJune 26, 2025 | money.usnews.comTNXP - Tonix Pharmaceuticals Holding Corp News - MorningstarJune 26, 2025 | morningstar.comMTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.3% - Time to Sell?June 25, 2025 | marketbeat.comRhumbline Advisers Invests $244,000 in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)June 25, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 5% - What's Next?June 24, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.5% - Should You Sell?June 23, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3% - What's Next?June 20, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 1.7% - Here's What HappenedJune 19, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 1.7% - Time to Sell?June 18, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 9.9% Higher - Still a Buy?June 16, 2025 | marketbeat.comTonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A BuyJune 16, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCEMI, MBRX, TNXP, and NHWK Company DescriptionsChembio Diagnostics NASDAQ:CEMIChembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.Moleculin Biotech NASDAQ:MBRX$0.32 +0.02 (+7.49%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$0.32 0.00 (-1.39%) As of 07/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.NightHawk Biosciences NYSE:NHWKNightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.Tonix Pharmaceuticals NASDAQ:TNXP$37.30 +1.32 (+3.67%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$36.64 -0.66 (-1.78%) As of 07/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
